Trials / Terminated
TerminatedNCT04892017
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
A Phase 1/2, First-in-Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Deciphera Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open label, first in human (FIH) study of inlexisertib as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in participants with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inlexisertib | Oral Tablet Formulation |
| DRUG | Trametinib | Oral Tablet Formulation |
| DRUG | Binimetinib | Oral Tablet Formulation |
| DRUG | Sotorasib | Oral Tablet Formulation |
Timeline
- Start date
- 2021-06-15
- Primary completion
- 2026-03-30
- Completion
- 2026-03-30
- First posted
- 2021-05-19
- Last updated
- 2026-04-08
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04892017. Inclusion in this directory is not an endorsement.